<ENAMEX TYPE="ORGANIZATION">Bio-Technology General Corp.</ENAMEX>, a health-care products concern, named <ENAMEX TYPE="PERSON">Christopher Illick</ENAMEX> to its five-member board.
Mr. <ENAMEX TYPE="PERSON">Illick</ENAMEX>, general counsel and corporate secretary of <ENAMEX TYPE="ORGANIZATION">Clarendon America Insurance Co.</ENAMEX>, fills the seat vacated by <ENAMEX TYPE="PERSON">Frederick R. Adler</ENAMEX>. Mr. <ENAMEX TYPE="PERSON">Adler</ENAMEX>, who resigned, is a venture capitalist who controls 13.4% of <ENAMEX TYPE="ORGANIZATION">Bio-Technology</ENAMEX> common.
The company said it is waiting to hear from the <ENAMEX TYPE="ORGANIZATION">Securities and Exchange Commission</ENAMEX> about <ENAMEX TYPE="ORGANIZATION">Bio-Technology</ENAMEX>'s plan for debt restructuring. Major holders have approved the plan. Without such a restructuring or additional financing, the company faced the prospect of a bankruptcy-law filing.
